Thomas Mathew, MD
Internal Medicine · New Hyde Park, NYNPI 1245282136
Payments from drug & device makers
Across 853 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$2K
- Boehringer Ingelheim$2K
- Medtronic$2K
- Abbott$1K
- GSK$1K
- plus $10K from 50 others
What the payments were for
- Travel & lodging$1,3456%
- Food & beverage$18,94591%
- Education$4302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$848
- FREESTYLE LIBRE 3$566
- INPEN SMART INSULIN DELIVERY SYSTEM$402
- TEPEZZA$375
- Kerendia$372
- TZIELD$269
- JARDIANCE$250
- Repatha$250
- LOKELMA$247
- FARXIGA$247
- DEXCOM G6 TRANSMITTER$244
- CeQur Simplicity$187
- Pogo Automatic Blood Glucose Monitoring System$127
- XARELTO$125
- EVENITY$119
- Prolia$118
- INVOKANA$106
How this compares
$20,720 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 459 | $590,070 |
| TrulicityDulaglutide | 274 | $482,439 |
| JardianceEmpagliflozin | 317 | $432,229 |
| OzempicSemaglutide | 202 | $395,081 |
| JanumetSitagliptin Phos/Metformin Hcl | 289 | $354,302 |
| JanuviaSitagliptin Phosphate | 143 | $168,932 |
| MounjaroTirzepatide | 77 | $144,038 |
| EliquisApixaban | 95 | $132,959 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $122,752 |
| TradjentaLinagliptin | 86 | $110,035 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $88,438 |
| Breo ElliptaFluticasone/Vilanterol | 103 | $85,132 |
| JentaduetoLinagliptin/Metformin Hcl | 70 | $83,404 |
| LokelmaSodium Zirconium Cyclosilicate | 60 | $77,470 |
| RybelsusSemaglutide | 30 | $72,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Breztri Aerosphere, Brilinta | $2,455 | $703,878555 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Jentadueto Xr, Synjardy Xr | $1,848 | $660,400504 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $890 | $626,477351 claims |
| MerckJanumet, Januvia, Janumet Xr | $284 | $586,726488 claims |
| Novo NordiskOzempic, Rybelsus | $904 | $467,607232 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,042 | $223,137215 claims |
| PfizerEliquis | $324 | $132,95995 claims |
| AbbVieLinzess, Creon, Ubrelvy | $586 | $95,93774 claims |
| NovartisEntresto | $705 | $58,58246 claims |
| Johnson & JohnsonXarelto | $609 | $52,37147 claims |
| AmgenProlia | $2,102 | $37,09922 claims |
| Astellas Pharma US IncMyrbetriq | $606 | $31,11846 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New Hyde Park
- Nagashree SeetharamuNew Hyde Park$2.5M
- Janice WangNew Hyde Park$2.1M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.